Most Active

Cardiff Oncology Scores FDA Fast Track for Onvansertib in RAS-Mutated Colorectal Cancer, Stock Surges 12%

Read this in the Market Flux app

Cardiff Oncology, Inc. $CRDF

$0.85+17.75%as of publication

5D Change
+7.09%
Notional
$21.15M

Cardiff Oncology received FDA Fast Track designation for onvansertib in combination with FOLFIRI and bevacizumab as a first-line treatment for RAS-mutated metastatic colorectal cancer, sending shares up 12.3% in pre-market trading on November 16, 2026. The designation was supported by randomized Phase 2 trial data showing a 72.2% confirmed overall response rate for the onvansertib combination versus 42.1% for the standard-of-care arm.

The company presented at the UBS Global Biopharma Conference the same day, with President and CEO Mani Mohindru outlining the regulatory progress and the path toward a pivotal registrational trial. The planned Phase 3 study initiation and durability of progression-free survival are now viewed as the key future valuation drivers for the stock.

© AI-generated summary is provided by Market Flux

Sources

  1. Seeking AlphaCardiff Oncology, Inc. (CRDF) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
  2. BioStocks$CRDF Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
  3. OpenOutcrier$CRDF (+12.3% pre) Cardiff Oncology wins FDA Fast Track for RAS-mutated colorectal cancer drug
  4. BPharmCatalyst$HELP announced positive Phase 3 APPROACH data for HLP003 (deuterated psilocin) as an adjunct in major depressive disorder (n=222). The trial met its primary endpoint with a 7.6-point placebo-adjusted MADRS reduction at Week 6 (p<0.0001), sustained at 7.0 points through Week 12. Week 6 response and remission rates were 56.3% and 50.9% versus 28.2% and 18.2% for placebo, with onset by Day 2. Three treatment-related SAEs occurred; Phase 3 EMBRACE results are expected in Q4 2027. $ACRS $LXEO $CRDF $OCS $HELP $DRTS $AKAN $INAB $XRTX $ADXN See More Pre-market Movers at BioPharmCatalyst in the Articles Menu
  5. InvestingCardiff Oncology at UBS conference: phase iii push gains speed